Literature DB >> 29996002

Study of the possible link of 25-hydroxyvitamin D with Epstein-Barr virus and human herpesvirus 6 in patients with multiple sclerosis.

S Pérez-Pérez1, M I Domínguez-Mozo1, M Á García-Martínez1, Y Aladro2, M Martínez-Ginés3, J M García-Domínguez3, C López de Silanes4, I Casanova4, I Ortega-Madueño5, L López-Lozano5, M J Torrejón5, R Arroyo6, R Álvarez-Lafuente1.   

Abstract

BACKGROUND AND
PURPOSE: Although the causes of multiple sclerosis (MS) remain partially unknown, environmental and genetic factors are thought to play a role in its aetiopathogenesis. Hypovitaminosis D, Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6) infections have been described as possible MS triggers. Our aim was to analyse the possible link between 25-hydroxyvitamin D [25(OH)D] and viruses in patients with MS.
METHODS: We included 482 patients with MS in a 2-year study. Serum samples were collected to analyse 25(OH)D levels and, according to sample availability, antibody titres against EBV and HHV-6 by enzyme-linked immunosorbent assay. DNA was extracted from blood in order to analyse EBV and HHV-6 viral load by quantitative real-time polymerase chain reaction and to genotype MS-related single nucleotide polymorphisms (rs3135388, rs2248359 and rs12368653) when possible.
RESULTS: The 25(OH)D levels were significantly higher in the first semester of the year than in the second. Carriers of the risk allele rs2248359-C showed lower 25(OH)D levels than non-carriers. For EBV, viral load was significantly higher when 25(OH)D levels were low, demonstrating an inverse correlation between 25(OH)D levels and EBV load.
CONCLUSIONS: The 25(OH)D levels could be involved in the regulation of EBV replication/reactivation in patients with MS.
© 2018 EAN.

Entities:  

Keywords:  Epstein-Barr virus; human herpesvirus 6; multiple sclerosis; vitamin D

Mesh:

Substances:

Year:  2018        PMID: 29996002     DOI: 10.1111/ene.13749

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

Review 1.  Vitamin D as a Risk Factor for Multiple Sclerosis: Immunoregulatory or Neuroprotective?

Authors:  Sara E Gombash; Priscilla W Lee; Elizabeth Sawdai; Amy E Lovett-Racke
Journal:  Front Neurol       Date:  2022-05-16       Impact factor: 4.086

Review 2.  An Update on Vitamin D and Disease Activity in Multiple Sclerosis.

Authors:  Joost Smolders; Øivind Torkildsen; William Camu; Trygve Holmøy
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

3.  Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis.

Authors:  Max Mimpen; Linda Rolf; Geert Poelmans; Jody van den Ouweland; Raymond Hupperts; Jan Damoiseaux; Joost Smolders
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

4.  Epstein-Barr Virus Load Correlates with Multiple Sclerosis-Associated Retrovirus Envelope Expression.

Authors:  Silvia Pérez-Pérez; María Inmaculada Domínguez-Mozo; María Ángel García-Martínez; Rubén Ballester-González; Israel Nieto-Gañán; Rafael Arroyo; Roberto Alvarez-Lafuente
Journal:  Biomedicines       Date:  2022-02-05

5.  Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study.

Authors:  María Inmaculada Domínguez-Mozo; Lorena López-Lozano; Silvia Pérez-Pérez; Ángel García-Martínez; María José Torrejón; Rafael Arroyo; Roberto Álvarez-Lafuente
Journal:  Front Immunol       Date:  2022-09-14       Impact factor: 8.786

Review 6.  Controversial Effects of Vitamin D and Related Genes on Viral Infections, Pathogenesis, and Treatment Outcomes.

Authors:  Choongho Lee
Journal:  Nutrients       Date:  2020-03-30       Impact factor: 5.717

7.  Epidemiology of multiple sclerosis and vitamin D levels in Lanzarote, Canary Islands, Spain.

Authors:  Silvia Pérez-Pérez; Pablo Eguia Del Rio; María Inmaculada Domínguez-Mozo; María Ángel García-Martínez; María Francisca Zapata-Ramos; Maria Jose Torrejon; Rafael Arroyo; Roberto Alvarez-Lafuente
Journal:  PeerJ       Date:  2019-12-18       Impact factor: 2.984

8.  Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.

Authors:  Maria Inmaculada Dominguez-Mozo; Silvia Perez-Perez; Luisa María Villar; Begoña Oliver-Martos; Noelia Villarrubia; Fuencisla Matesanz; Lucienne Costa-Frossard; María Jesús Pinto-Medel; María Isabel García-Sánchez; Isabel Ortega-Madueño; Lorena Lopez-Lozano; Angel Garcia-Martinez; Guillermo Izquierdo; Óscar Fernández; Jose Carlos Álvarez-Cermeño; Rafael Arroyo; Roberto Alvarez-Lafuente
Journal:  Sci Rep       Date:  2020-08-28       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.